Does Latuda Cause Elevated ALT?
The FDA-approved prescribing information for Latuda (lurasidone) does not list elevated ALT or hepatotoxicity as a reported adverse reaction in clinical trials, indicating this is not a recognized or common side effect of the medication 11.
Evidence from Clinical Trials
The comprehensive adverse reaction tables from Latuda's FDA label across multiple populations (adults and adolescents with schizophrenia, adults and pediatrics with bipolar depression) do not include ALT elevation, liver enzyme abnormalities, or hepatotoxicity among the documented adverse events 11. The most common adverse reactions reported were:
- Extrapyramidal symptoms (9-14%)
- Akathisia (5-12%)
- Somnolence (5-15%)
- Nausea (10-17%)
- Weight changes (3-7%)
Clinical Significance
Unlike many psychotropic medications that require routine liver function monitoring, Latuda does not appear to carry clinically meaningful hepatotoxic risk. The absence of ALT elevation from the adverse event profile across multiple large clinical trials spanning different age groups and indications strongly suggests this is not a concern with lurasidone therapy 11.
Metabolic Profile Advantage
Lurasidone is actually noted for its favorable metabolic profile compared to other atypical antipsychotics, with low risk of metabolic abnormalities 23. This favorable profile extends to hepatic effects, as evidenced by the lack of reported liver enzyme elevations.
Practical Implications
- No baseline liver function testing required before initiating Latuda
- No routine ALT monitoring needed during treatment
- If ALT elevation occurs in a patient on Latuda, investigate alternative causes (other medications, viral hepatitis, fatty liver disease, alcohol use)
- The primary safety concerns with Latuda remain extrapyramidal symptoms and akathisia, not hepatotoxicity
In summary: Elevated ALT is not a recognized adverse effect of Latuda based on extensive clinical trial data, and routine liver monitoring is not indicated.